Correlation Between Aquestive Therapeutics and Skye Bioscience,

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Aquestive Therapeutics and Skye Bioscience, at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Aquestive Therapeutics and Skye Bioscience, into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Aquestive Therapeutics and Skye Bioscience, Common, you can compare the effects of market volatilities on Aquestive Therapeutics and Skye Bioscience, and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Aquestive Therapeutics with a short position of Skye Bioscience,. Check out your portfolio center. Please also check ongoing floating volatility patterns of Aquestive Therapeutics and Skye Bioscience,.

Diversification Opportunities for Aquestive Therapeutics and Skye Bioscience,

0.8
  Correlation Coefficient

Very poor diversification

The 3 months correlation between Aquestive and Skye is 0.8. Overlapping area represents the amount of risk that can be diversified away by holding Aquestive Therapeutics and Skye Bioscience, Common in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Skye Bioscience, Common and Aquestive Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Aquestive Therapeutics are associated (or correlated) with Skye Bioscience,. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Skye Bioscience, Common has no effect on the direction of Aquestive Therapeutics i.e., Aquestive Therapeutics and Skye Bioscience, go up and down completely randomly.

Pair Corralation between Aquestive Therapeutics and Skye Bioscience,

Given the investment horizon of 90 days Aquestive Therapeutics is expected to generate 0.79 times more return on investment than Skye Bioscience,. However, Aquestive Therapeutics is 1.26 times less risky than Skye Bioscience,. It trades about -0.12 of its potential returns per unit of risk. Skye Bioscience, Common is currently generating about -0.12 per unit of risk. If you would invest  498.00  in Aquestive Therapeutics on September 30, 2024 and sell it today you would lose (146.00) from holding Aquestive Therapeutics or give up 29.32% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthStrong
Accuracy100.0%
ValuesDaily Returns

Aquestive Therapeutics  vs.  Skye Bioscience, Common

 Performance 
       Timeline  
Aquestive Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Aquestive Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unsteady performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in January 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.
Skye Bioscience, Common 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Skye Bioscience, Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain rather sound which may send shares a bit higher in January 2025. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders.

Aquestive Therapeutics and Skye Bioscience, Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Aquestive Therapeutics and Skye Bioscience,

The main advantage of trading using opposite Aquestive Therapeutics and Skye Bioscience, positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Aquestive Therapeutics position performs unexpectedly, Skye Bioscience, can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Skye Bioscience, will offset losses from the drop in Skye Bioscience,'s long position.
The idea behind Aquestive Therapeutics and Skye Bioscience, Common pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.

Other Complementary Tools

Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk